Icon Advisers’s Supernus Pharmaceuticals SUPN Stock Holding History

Icon Advisers’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-52,774	Closed	-$1.25M	–	293
2019 Q4	$1.25M	Hold	52,774	–	–	0.18%	168
2019 Q3	$1.45M	Sell	52,774 -24,300	-32%	-$720K	0.21%	151
2019 Q2	$2.55M	Sell	77,074 -6,200	-7%	-$212K	0.24%	104
2019 Q1	$2.92M	Hold	83,274	–	–	0.29%	91
2018 Q4	$2.77M	Buy	83,274 +6,274	+8%	+$270K	0.29%	93
2018 Q3	$3.88M	Buy	+77,000	New	+$3.8M	0.33%	79

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Icon Advisers's SUPN Position: Q1 2020 in Review

Icon Advisers sold out of Supernus Pharmaceuticals (SUPN) in Q1 2020, closing a stake of 52,774 shares — an estimated $1.25M sold.

Icon Advisers first reported a position in SUPN in Q3 2018 and held it in 6 quarters. The position peaked at $3.88M in Q3 2018. 208 funds tracked by Wall St. Rank hold SUPN as of Q1 2020.

Icon Advisers reported no remaining Supernus Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Icon Advisers sold 52,774 Supernus Pharmaceuticals shares in Q1 2020, an estimated $1.25M.
Icon Advisers first reported a position in Supernus Pharmaceuticals in Q3 2018 and held it in 6 quarters.
Icon Advisers's Supernus Pharmaceuticals position peaked at $3.88M in Q3 2018.
208 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2020.

Based on Icon Advisers's 13F filing for Q1 2020, filed 1 May 2020.